These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Ilowite N; Porras O; Reiff A; Rudge S; Punaro M; Martin A; Allen R; Harville T; Sun YN; Bevirt T; Aras G; Appleton B Clin Rheumatol; 2009 Feb; 28(2):129-37. PubMed ID: 18766426 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T; Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090 [TBL] [Abstract][Full Text] [Related]
8. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB; Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469 [TBL] [Abstract][Full Text] [Related]
9. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180 [TBL] [Abstract][Full Text] [Related]
10. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of anakinra as first-line or second-line therapy for systemic onset juvenile idiopathic arthritis - data from the German BIKER registry. Atemnkeng Ntam V; Klein A; Horneff G Expert Opin Drug Saf; 2021 Jan; 20(1):93-100. PubMed ID: 33148061 [No Abstract] [Full Text] [Related]
14. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Tarp S; Amarilyo G; Foeldvari I; Christensen R; Woo JM; Cohen N; Pope TD; Furst DE Rheumatology (Oxford); 2016 Apr; 55(4):669-79. PubMed ID: 26628580 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Vastert SJ; de Jager W; Noordman BJ; Holzinger D; Kuis W; Prakken BJ; Wulffraat NM Arthritis Rheumatol; 2014 Apr; 66(4):1034-43. PubMed ID: 24757154 [TBL] [Abstract][Full Text] [Related]
16. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. Kearsley-Fleet L; Beresford MW; Davies R; De Cock D; Baildam E; Foster HE; Southwood TR; Thomson W; Hyrich KL Rheumatology (Oxford); 2019 Jan; 58(1):94-102. PubMed ID: 30137641 [TBL] [Abstract][Full Text] [Related]
17. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Hedrich CM; Bruck N; Fiebig B; Gahr M Rheumatol Int; 2012 Nov; 32(11):3525-30. PubMed ID: 22083619 [TBL] [Abstract][Full Text] [Related]
18. Early Treatment and IL1RN Single-Nucleotide Polymorphisms Affect Response to Anakinra in Systemic Juvenile Idiopathic Arthritis. Pardeo M; Rossi MN; Pires Marafon D; Sacco E; Bracaglia C; Passarelli C; Caiello I; Marucci G; Insalaco A; Perrone C; Tulone A; Prencipe G; De Benedetti F Arthritis Rheumatol; 2021 Jun; 73(6):1053-1061. PubMed ID: 33615724 [TBL] [Abstract][Full Text] [Related]
19. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of interleukin-1 antagonists in rheumatoid arthritis: a systematic review and meta-analysis. Nikfar S; Saiyarsarai P; Tigabu BM; Abdollahi M Rheumatol Int; 2018 Aug; 38(8):1363-1383. PubMed ID: 29737371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]